Results 1 to 10 of about 15,580 (252)

Remote severity assessment in atopic dermatitis: Validity and reliability of the remote Eczema Area and Severity Index and Self-Administered Eczema Area and Severity IndexCapsule Summary [PDF]

JAAD International, 2023
Background: Reliable assessment of atopic dermatitis (AD) severity is necessary for clinical practice and research. Valid and reliable remote assessment is essential to facilitate remote care and research.
Aviël Ragamin, MD, Renske Schappin, PhD, N. Tan Nguyen, MD, Anouk E.M. Nouwen, MD, Lisanne F. Hoekstra, MD, Marie L.A. Schuttelaar, MD, PhD, Suzanne G.M.A. Pasmans, MD, PhD   +6 more
doaj   +8 more sources

Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials [PDF]

Acta Dermato-Venereologica
The ADvocate trials (NCT04146363, NCT04178967) investigated adults/adolescents with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab (LEB) monotherapy, using percent improvement in the Eczema Area and Severity Index (EASI).
Diamant Thaçi, Luis Puig, Sei-ichiro Motegi, Kim Papp, Linda Stein Gold, Leon Kircik, Howard Sofen, Pablo Fernández-Peñas, Pedro Herranz, Christian Vestergaard, Yu-Huei Huang, Martin Dossenbach, Hany Elmaraghy, Gaia Gallo, Maria Jose Rueda, Marta Casillas, Chao Yang, Helena Agell, Meritxell Falqués, Audrey Nosbaum   +19 more
doaj   +9 more sources

Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index

Acta Dermato-Venereologica, 2019
Dupilumab is approved for uncontrolled moderate-to-severe atopic dermatitis (AD); cyclosporine is approved for severe AD for
Lieneke F.M. Ariëns, Abhijit Gadkari, Harmieke van Os-Medendorp, Rajeev Ayyagari, Emi Terasawa, Andreas Kuznik, Zhen Chen, Gaëlle Bégo-Le Bagousse, Yufang Lu, Elena Rizova, Neil M.H. Graham, Gianluca Pirozzi, Marjolein De Bruin-Weller, Laurent Eckert   +13 more
doaj   +5 more sources

Translating the Investigator's Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis. [PDF]

Dermatol Ther (Heidelb), 2021
Atopic dermatitis (AD) severity was measured in two phase 3 US studies of crisaborole ointment, 2%, in patients aged ≥ 2 years using the Investigator's Static Global Assessment (ISGA), an FDA-recommended scale. Eczema Area and Severity Index (EASI) is a validated scale used globally to assess AD severity in clinical trials.
Thyssen JP, Zang C, Neary MP, Bushmakin AG, Cappelleri JC, Cha A, Russo C, Luger TA.   +7 more
europepmc   +5 more sources

Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children. [PDF]

J Am Acad Dermatol, 2020
Accurately documenting pediatric atopic dermatitis (AD) severity is important, but research tools, such as Eczema Area and Severity Index (EASI), are too time consuming for clinical settings. Product of the Physician Global Assessment and affected percentage of body surface area (PGA×BSA) is a new, rapid measure of psoriasis severity.To evaluate an ...
Suh TP, Ramachandran D, Patel V, Jackson KL, Rangel SM, Fishbein AB, Paller AS.   +6 more
europepmc   +5 more sources

Modeling of Temporal Exposure to the Ambient Environment and Eczema Severity

JID Innovations, 2022
Atopic eczema is a common and complex disease. Missing genetic hereditability and increasing prevalence in industrializing nations point toward an environmental driver.
Bjorn R. Thomas, Xiang L. Tan, Shagayegh Javadzadeh, Elizabeth J. Robinson, Bryan S. McDonald, Malvina A. Krupiczojc, Syedia R. Rahman, Samiha Rahman, Rehana A. Ahmed, Rubina Begum, Habiba Khanam, David P. Kelsell, Jonathan Grigg, Robert J. Knell, Edel A. O’Toole   +14 more
doaj   +3 more sources

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Journal of Dermatological Treatment
Background Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and ...
Andrew Blauvelt, Leon Kircik, Todd Schlesinger, Evangeline Pierce, Russel Burge, Michael Behling, Amber Reck Atwater, Hany ElMaraghy, April Armstrong   +8 more
doaj   +3 more sources

Expression Analysis of CCL27: A Sensitive biomarker in distinguishing between psoriasis and atopic dermatitis [PDF]

Research Journal of Applied Biotechnology, 2022
Background and objective: Eczema and psoriasis are heterogeneous cutaneous inflammatory disorders with broad and occasionally overlapping diagnostic criteria, making it difficult to distinguish psoriasis from eczema.
Ayman Elrefaei, Manal Elhamshary, Hisham Ismail, Mahmoud Nasr, Ghada Nasr   +4 more
doaj   +1 more source

Colonization by S. Aureusincreases the EASI and the number of appointments by patients with atopic dermatitis: cohort with 93 patients [PDF]

Anais Brasileiros de Dermatologia, 2013
BACKGROUND:Atopic dermatitis leads to epidermal barrier dysfunction and bacteria colonization. The relationship of the last factor with the severity of the disease and the frequency of exacerbation is not fully known.OBJECTIVES:Verify the severity of the
Caroline Lipnharski, Pedro Alves d'Azevedo, Vanessa Petry Quinto, Giancarlo Bessa, Renan Rangel Bonamigo   +4 more
doaj   +1 more source

Role of Eosinophil Relative Count and Neutrophil-to-Lymphocyte Ratio in the Assessment of Severity of Atopic Dermatitis

Acta Dermato-Venereologica, 2021
The aim of this study is to elucidate the relationship between 2 different types of severity-indicating parameters (i.e. between subjective and objective severity-indicating parametersin patients with atopic dermatitis.
Sanae Inokuchi-Sakata, Yozo Ishiuji, Michie Katsuta, Budiman Kharma, Ken-ichi Yasuda, Mitsutoshi Tominaga, Kenji Takamori, Yoshimasa Nobeyama, Akihiko Asahina   +8 more
doaj   +1 more source